Table 1.

Comparison of clinical features, antibodies and CSF data, MRI findings and outcome of steroid therapy in idiopathic ON

	MOG antibodies
	Negative (n=21)	Positive (n=8)	p Value
Total	21 (72.4%)	8 (27.6%)	–
Male:female	12:9	2:6	0.130
Age
Range	22–84	16–65	–
Median	51.0	31.0	0.052
Prodromic infection	3 (14.3%)	3 (37.5%)	0.179
Underlying disease
Diabetes mellitus	4 (19.0%)	1 (12.5%)	0.689
Autoimmune disorders	2 (9.5%)	1 (12.5%)	0.821
Malignancy	4 (19.0%)	2 (25.0%)	0.734
Symptoms
Visual disturbance	21 (100%)	8 (100%)	–
Optic pain	2 (9.5%)	5 (62.5%)	0.001
Serum AQP4 antibodies	0 (0%)	1 (12.5%)	0.106
CSF examination
Pleocytosis (>5/μL)	3 (14.3%)	3 (37.5%)	0.179
MBP high level (>102 pg/mL)	0 (0%)	3 (37.5%)	0.021
Oligoclonal band	1 (5.2%) (n=19)	0 (0%)	0.527
Abnormal intensity on MRI
Optic nerve	14 (66.7%)	7 (87.5%)	0.278
Cerebrum	7 (33.3%)	2 (25.0%)	0.840
Spinal cord	0 (0%)	1 (12.5%)	0.106
Therapies in acute phase
Steroid pulse	17 (80.9%)	8 (100%)	0.196
Oral prednisolone	3 (14.2%)	0 (0%)	0.262
Plasma exchange	0 (0%)	1 (12.5%)	0.106
Good or complete response to steroid therapy:	17 (81.0%)	7 (87.5%)	0.870
Recurrence	3 (14.3%)	2 (25.0%)	0.512

Oral prednisolone; 20 mg/day.

AQP4, aquaporin-4; CSF, cerebrospinal fluid; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; ON, optic neuritis.